Experimental Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, United States.
Experimental Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, United States.
Mol Immunol. 2019 Sep;113:31-37. doi: 10.1016/j.molimm.2018.03.025. Epub 2018 Apr 5.
The ability to mount an effective anti-tumor immune response requires coordinate control of CD4 T cell and CD8 T cell function by antigen presenting cells (APCs). Unfortunately, tumors create an immunosuppressive microenvironment that helps protect tumor cells from immune recognition. In many cases this defect can be traced back to a failure of APCs (most importantly dendritic cells (DCs)) to recognize, process, and present tumor antigens to T cells. In this review, we will summarize work addressing the role of different DC subsets in anti-tumor immunity and the various mechanisms used by tumor cells to suppress the ability of APCs to stimulate potent anti-tumor T cell responses.
为了能够有效地引发抗肿瘤免疫反应,抗原提呈细胞(APCs)需要协调控制 CD4 T 细胞和 CD8 T 细胞的功能。不幸的是,肿瘤会产生一种免疫抑制微环境,从而帮助肿瘤细胞逃避免疫识别。在许多情况下,这种缺陷可以追溯到 APC(最重要的是树突状细胞(DC))无法识别、处理和向 T 细胞呈递肿瘤抗原。在这篇综述中,我们将总结不同 DC 亚群在抗肿瘤免疫中的作用,以及肿瘤细胞用于抑制 APC 刺激有效抗肿瘤 T 细胞反应的各种机制。